http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
Xenetic Biosciences Announces Adjournment of Annual Meeting of Stockholders until Wednesday, August 16, 2017
-
Xenetic Biosciences Commences Patient Enrollment in Phase 2 Study Evaluating XBIO-101 in Conjunction with Progestin Therapy for the Treatment of Endometrial Cancer
-
Xenetic Biosciences (XBIO) Says Partner Shire (SHPG) Reports Positive Phase 1/2 Study Evaluating SHP656 to Treat Hemophilia A
-
Xenetic Biosciences Receives Program Update from Partner Shire’s Phase 1/2 Study Evaluating SHP656 in Development as a Long-acting Treatment for Hemophilia A
-
Xenetic Biosciences Reports 2017 First Quarter Financial Results and Provides Business Update
-
Xenetic Biosciences to Host 2017 First Quarter Update Conference Call
-
Xenetic Biosciences Presents Case Study of PolyXen™ Platform Technology at the 13th Annual Protein Engineering Summit (PEGS) Boston
-
Xenetic Biosciences’ PolyXen™ Platform Technology Accepted for Poster Presentation at the 13th Annual Protein Engineering Summit (PEGS) Boston
-
Xenetic Biosciences (XBIO) Names James F. Parslow as CFO
-
Xenetic Biosciences Expands Executive Management Team with Appointment of James F. Parslow, MBA, CPA as Chief Financial Officer
-
Xenetic Biosciences Reports 2016 Year End Financial Results and Provides Business Update
-
Xenetic Biosciences to Ring Nasdaq Stock Market Opening Bell on March 30, 2017
-
Xenetic Biosciences Provides Update on Patent Portfolio Development
-
OPKO Health's GeneDx to have Significant Presence at ACMG 2017
-
OPKO Health’s GeneDx Announces Participation in Illumina’s iHope Program on International Rare Disease Day
-
OPKO Health's (OPK) GeneDx Enters Pact with Wellcome Trust Sanger Institute
-
OPKO’S GeneDx Announces Research Collaboration with the Wellcome Trust Sanger Institute
-
Xenetic Biosciences Reports Third Quarter Financial Results and Provides Business Update
-
PJSC Pharmsynthez Completes Follow Up and Data Analysis From a Phase 2 Study of Novel Therapeutic Vaccine Xemys(TM) for Multiple Sclerosis
-
OPKO (OPK) Takes Minority Stake in Xenetic Biosciences
-
OPKO Health Acquires Interest in Xenetic
-
Cocrystal Pharma Announces Late Breaking Abstract at AASLD Meeting (OPK) (TEVA)
-
Cocrystal Pharma Announces Late Breaking Abstract at AASLD Liver Meeting
-
Cocrystal Pharma Announces Appointment of Douglas Mayers, M.D., as Chief Medical Officer
-
Market Wrap: IMF Calls on Fed to Delay Rate Hike; DISH, T-Mobile in M&A Talk; Initial Claims Outpace Ahead of Nonfarm Numbers
-
Pre-Open Stock Movers 06/04: (BRLI) (AVEO) (FIVE) Higher; (MCP) (DRWI) (OPK) Lower (more...)
-
Streetinsider.com's Hot Lunchtime Reads 3/26: (WBAI) (NSR) (SNDK) (TWTR)
-
Pre-Open Stock Movers 12/15: (TLM) (OPK) (CRUS) Higher; (UPIP) (XCO) (F) Lower (more...)
-
Pre-Open Stock Movers 12/16: (PATH) (LSI) (AER) Higher; (PIP) (CRUS) (TWTR) Lower (more...)

